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NON-MYELOABLATIVE STEM CELL TRANSPLANTATION IN NEWLY ES-
TABLISHED DONOR STROMAL MICROENVIRONMENT FOR FACILITA-
TION OF HEMATOPOIETIC RECONSTITUTION
Slavin, S., Shapira, M.Y., Samuel, S., Kurkalli, B., Gurevitch, O., Or,
R. Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Following allogeneic stem cell transplantation (SCT) migrate to
the hematopoietic microenvironment in bones, but the stroma
remains of host origin. We hypothesized that replacement of host
with donor stromal microenvironment supporting and regulating
hematopoiesis may enhance engraftment and differentiation of
bone marrow cells (BMC), especially in patients with myeloﬁbro-
sis. Our earlier work suggested that SCT with donor stromal
microenvironment modiﬁes GVHD. We have recently docu-
mented that transplantation of BMC mixed with demineralized
bone matrix (DBM) may be sufﬁcient for formation of new bone
and hematopoietic mircoenvironment. Tested in rats, implantation
of DBM/BMC composite intraosseously or under the kidney cap-
sule resulted in new bone formation containing donor hematopoi-
etic tissue. Based on the murine data, we introduced the use of
intra-osseous transplantation of DBM/BMC for patients with ex-
isting or anticipated marrow failure, such as myeloﬁbrosis, follow-
ing non-myeloablative conditioning (NST). Our 1st patient was 54
yrs old woman with RAEB-T and myeloid ﬁbrosis, with no hema-
tologic reconstitution following NST (ﬂudarabine, busulfex &
ATG) until week 4. Intraosseous (femora and pelvis) transplan-
tation of DBM/BMC was accomplished with no further condition-
ing from the same donor, assuming the problem was engraftment
failure rather than rejection. Early 3-lineage reconstitution of do-
nor (male) cells was conﬁrmed within one week. Currently, the
patient is more than 2 years out with mild chronic GVHD, with
100 percent normal male karyotype. Bone biopsy, laser capture
microdissection and PCR revealed 100 percent donor-derived
blood cells, stroma and bone cells. Two additional patients under-
went successful intra-osseous DBM/BMC transplantation into one
femur following NST, with fast 3-lineage engraftment. Procedures
were uneventful. All patients are disease free, with 100 percent
donor type cells. Considering our experimental and clinical expe-
rience, intra-osseous transplantation of DBM/BMC may provide a
new tool for enhancing allogeneic hematopoietic reconstitution,
especially for patients with myeloﬁbrosis.
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ISOLATION OF OLIGODENDROCYTE PRECURSORS FROM UMBILICAL
CORD BLOOD
Hall, J.G., Crapnell, K.B., Staba, S., Kurtzberg, J. Duke University
Medical Center, Durham, NC
Introduction: The treatment of childhood leukodystrophies
with umbilical cord blood (UCB) transplantation has resulted in
cognitive and functional stabilization, but with minimal improve-
ment in neurologic and motor deﬁcits preexisting at the time of
transplant. The lack of improvement in motor function may be due
to the irreversible damage to motor neurons before transplanta-
tion. Conversely, trafﬁcking of transplanted cells may not occur for
months after transplant, missing a potential therapeutic window.
The delivery of cells directly to the brain may hasten engraftment
in and repair of neurologic tissue, facilitating clinical improvement
in these patients. We hypothesized that UCB contains cells capable
of differentiating into precursors of some neural lineages, speciﬁ-
cally oligodendrocytes, which could eventually be used for trans-
plantation in patients with these demyelinating or dismyelinating
diseases. To this end, we attempted to culture neural progenitor
cells from UCB ex vivo. Methods: Mononuclear cells were iso-
lated from fresh umbilical cord blood units with hespan and ﬁcoll
density gradient separation, and cultured in ﬂasks and LabTek®
chamber slides at a concentration of 3-4  106 cells/mL in media
containing platelet-derived growth factor (PDGF) (5ng/mL), neu-
rotrophin-3 (1ng/mL), tri-iodothyronine (30ng/mL), vascular en-
dothelial growth factor (VEGF) (10ng/mL), and 10% fetal calf
serum. An adherent cell population was observed after one week of
culture. Adherent cells grown on LabTek® slides were ﬁxed with
4% paraformaldehyde, stained and scored using immunocyto-
chemical techniques for the hematopoietic markers CD45 and
CD34, human leukocyte antigen (HLA) class I and II, microglial
markers CD68 and CD11b, the astrocyte marker GFAP, oligoden-
drocyte markers O1, O4, and myelin basic protein (MBP), and
neuronal markers NeuN and -tubulin III. Results: Approxi-
mately 60% of the isolated adherent cells appeared long and
spindle-like, many with branches extending from the cell body.
These cells displayed positive ﬂuorescent staining for CD45, O1,
O4, MBP, HLA I, and HLA II. The cells did not express CD34,
CD68, CD11b, GFAP, NeuN, or -tubulin III. Conclusions: The
pattern of staining observed in this UCB-derived cell population is
suggestive of oligodendrocyte differentiation. These cells may have
the potential for therapeutic trials in patients with leukodystrophies.
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A REQUIREMENT FOR THE SPLEEN IN PREVENTING SUSTAINED IM-
BALANCE OF B220 CELLS AND GR-1 CELLS DURING RECONSTITU-
TION FOLLOWING SYNGENEIC AND ALLOGENEIC BMT
Shatry, A.M., Van der Put, E., Riley, R.L., Jones, M., Levy, R.B.
University of Miami Medical School, Miami, FL
The murine spleen is an active hematopoietic compartment fol-
lowing BMT and a target for preferred engraftment by a sub-
set (Rhohi) of hematopoietic stem cells (HSC). To determine the
contribution of the spleen to hematopoietic reconstitution after
BMT, the relative pattern of donor cell reconstitution and pro-
genitor cell (PC) distribution was examined in splenectomized
(Splx) recipients. Two weeks post-BMT, removal of the spleen
results in signiﬁcant increases in marrow PC activity compared to
sham-Splx controls in syngeneic and allogeneic BMT. Peripheral
and BM distribution of donor cells representative of lymphoid
(B220) and myeloid (Mac-1/Gr-1) cells was then assessed to
3 months post-BMT. A signiﬁcant (p  0.05) elevation of cir-
culating B220 cells was present in Splx recipients from 14 to 90
dys post-BMT, declining to sham control levels by 100 dys
post-BMT. In contrast, the % of circulating granulocytes (Gr-1/
Mac-1) was signiﬁcantly lower in Splx compared to sham con-
trols to 100 dys post-BMT. Three months post-BMT, the mar-
row compartment in Splx recipients demonstrated 3x (p 
0.0001) increases in sIgMD cells, although differences in cir-
culating B220 cells among the two groups had then diminished
by this time point, indicating a preferential accumulation of
sIgMD cells in this compartment. Initial results examining
LPS-stimulated PBMC proliferation are consistent with elevated
levels of circulating B220 cells (100 dys), indicating the B cells
are functional in Splx recipients. Additionally, consistent with el-
evated mature “recirculating” B cells in the marrow compartment,
LPS-induced proliferation levels were signiﬁcantly higher (p 
0.05) in these Splx recipients at 100 dys post-BMT. The in vitro
response of BM cells to IL-7 in Splx recipients was signiﬁcantly
(p  0.05) elevated, suggesting that the effects of the spleen on
B220 cells may be “upstream” of marrow sIgMD cells. A
decline in BM cell proliferation in response to IL-3 also occurred,
thus paralleling the observed peripheral decline in mature myeloid
cell subsets. These data indicate that the absence of the spleen in
BMT recipients could prompt sustained imbalance in the relative
distribution of deﬁned populations of the lymphoid and myeloid
lineages. Thus the splenic compartment is important in BMT both
as a site of hematopoiesis and in the regulation of deﬁned periph-
eral populations of the lymphoid/myeloid lineage.
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COMPARISONS OF HEMATOPOIETIC SUPPORT BY ADIPOSE-DERIVED
AND BONE MARROW-DERIVED STROMA
Storms, R.W.1, Green, P.D.1, Foster, S.J.2, Gimble, J.M.2 1. Duke
University Medical Center, Durham, NC; 2. Artecel Sciences, Inc,
Durham, NC
Adipose-derived stromal (AdS) cells are multipotent mesodermal
progenitors with developmental potentials similar to those ascribed
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to bone marrow-derived stromal (MdS) cells. The bone marrow
mesenchyme supports hematopoietic stem cells and progenitors in
vivo and in vitro. The AdS are readily accessible from subcutaneous
fat but have not been fully characterized for hematopoietic sup-
port. We now directly compare the relative capacities of allogeneic
AdS and MdS to support hematopoiesis. In total, 4 preparations of
AdS and 4 preparations of MdS were used to complete these
studies. Support for primitive hematopoietic progenitors was mon-
itored in 5-week long-term culture (LTC) assays. CD34CD38neg
cells were puriﬁed from umbilical cord blood (UCB, n  8) to
establish duplicate cultures with 100 hematopoietic progenitors per
well in standard Dexter-type media. LTC cultures on MdS gave
rise to 67.1  19.8 CFU after 5 weeks. Parallel cultures on AdS
gave rise to 26.6  11.4 CFU. These frequencies approach statis-
tical signiﬁcance (p  0.054). Importantly, however, 30% of the
cultures initiated on AdS failed to support LTC. Thus, 100 CD34
CD38neg cells may deﬁne a limit-dilution for LTC activity on AdS
cells. In contrast, all cultures initiated on MdS supported LTC. In
shorter-term assays, parallel cultures were established using 10,000
CD34 linneg UCB cells for 12 days. The cultures were established
in DMEM/F12 media containing 10% serum. No exogenous cy-
tokines were used. The results are tabulated below. AdS and MdS
supported similar expansions of total hematopoietic (CD45) cells.
However, cultures established on MdS maintained higher percent-
ages of CD34 cells over the 12 day time course. Not surprisingly,
there was a strong association between the percentages of CD34
cells and the frequencies of CFU present at day 12 (AdS, r  0.81;
MdS, r  0.85). However, without exogenous cytokines these
stroma maintained but did not expand the total content of CFU.
Finally, both AdS and MdS encouraged the outgrowth of lymphoid
progenitors as monitored by the presence of CD7 CD34neg cells
as well as by the growth of NK (CD56) cells in secondary
cultures. Higher percentages of CD7 cells were noted on AdS
than on MdS. In total, these data suggest that AdS and MdS
provide similar hematopoietic support, although subtle distinctions
were noted. These studies provide a model that can be manipulated
to optimize hematopoietic expansion ex vivo.
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THROMBOTIC MICROANGIOPATHY (TMA) FOLLOWING ALLOGENEIC
STEM-CELL TRANSPLANTATION (SCT) IN THE ERA OF REDUCED-IN-
TENSITY CONDITIONING: THE INCIDENCE IS NOT REDUCED
Shimoni, A.1, Hardan, I.1, Yeshurun, M.1, Avigdor, A.1, Papatrypho-
nos, A.2, Tsolakis, F.I.3, Nagler, A.1 1. Chaim Sheba Medical Center,
Tel-Hashomer, Israel; 2. Archbishop Makarios III, Nicosia, Cyprus; 3.
Limassol General Hospital, Limassol, Cyprus
TMA is one of the most severe complications of SCT. Endothe-
lial cell injury caused by the toxic effects of high-dose chemo-
radiotherapy is likely the primary event in the pathogenesis. The
incidence, clinical settings, and risk factors for TMA in the era of
nonmyeloablative and reduced intensity conditioning (NST/RIC)
have not been well deﬁned. We collected data on 147 consecutive
SCTs for various hematologic malignancies. The diagnosis of
TMA required thrombocytopenia, elevated LDH level and frag-
mented red cells in peripheral blood ﬁlm. TMA occurred following
22 SCTs with a projected incidence of 20  4% in a median of 30
days after SCT. TMA occurred in 3 overlapping clinical settings:
classical multifactorial TMA, TMA associated with severe hepatic
GVHD, and TMA associated with second allogeneic SCT, with a
projected incidence of 8  3%, 73  14%, and 70  16% of pts
at risk, respectively. TMA occurred following 23  6% of NST/
RIC (14 of 84) and 16  5% of myeloablative conditioning (8 of
63) (p NS). Univariant analysis determined SCT from unrelated
donors, SCT during advanced/ active disease, second SCT within
6 months of a prior SCT, and acute GVHD as risk factors for
TMA. The last two factors remained signiﬁcant in a multivariant
model with hazard ratios of 6.4 and 14.5, respectively. Therapy
included withdrawal or reduction of cyclosporine dose and infusion
of cryoprecipitate poor plasma with a response rate of 23 percent.
4 of the non-responders were treated with plasma exchange and 2
responded. Overall, 32% of pts responded to any line of therapy.
Only 4 pts are currently alive. Ten died of complications related to
acute GVHD. Five died of bleeding complications; 4 of diffuse
alveolar hemorrhage (DAH) and one of CNS bleeding. One pt
died of cerebral TMA with refractory convulsions. The peri-TMA
mortality rate was 68  10%. Two additional pts later died of
relapse. SCT-associated TMA is a relatively common complication
with unsatisfactory therapy and grim prognosis. Fludarabine-based
NST/RIC does not confer a lesser risk for TMA. This unexpected
observation relates in part to the selective use of NST/RIC in older
pts, pts having a second SCT, extensive prior therapy or unrelated
donor SCT, all risk factors for TMA. Fludarabine, a major con-
stitute of these regimens, may also be involved in causing endo-
thelial damage and increasing the risk for TMA. Further explora-
tion of novel preventive and therapeutic measurements is required
in high-risk settings.
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EVALUATION OF THE PLATELET-SPECIFIC ANTIBODY RESPONSE IN
THROMBOCYTOPENIA FOLLOWING ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Yamazaki, R.1,2, Mori, T.1, Kuwana, M.2, Okazaki, Y.2, Kawakami,
Y.2, Ikeda, Y.1, Okamoto, S.1 1. Division of Hematology, Department of
Internal Medicine; 2. Division of Cellular Signaling, Institute for Ad-
vanced Medical Research, Keio University School of Medicine, Shinjuku-
ku, Tokyo, Japan
Thrombocytopenia is a common complication early and late after
allogeneic hematopoietic stem cell transplantation (allo-HSCT),
but its etiologies are largely unknown. In this study, a role of
anti-platelet antibody response in patients with thrombocytopenia
after allo-HSCT was examined by detecting antibodies to glyco-
protein IIb/IIIa (GPIIb/IIIa), a major platelet-speciﬁc autoantigen
in patients with idiopathic thrombocytopenic purpura (ITP). Fifty-
six patients with hematological malignancies who received allo-
HSCT were enrolled. Of these, 35 patients suffered from pro-
longed thrombocytopenia. As controls, 78 ITP patients and 52
healthy donors were also examined. Circulating B cells secreting
anti-GPIIb/IIIa antibodies were measured using enzyme-linked
immunospot assay, and anti-GPIIb/IIIa antibodies in platelet elu-
ates and plasma were detected by enzyme-linked immunosorbent
assay. Frequency of anti-GPIIb/IIIa antibody-producing B cells in
allo-HSCT patients was comparable to that in ITP patients, but
was signiﬁcantly higher than that in healthy donors (5.8  6.4 vs
8.2  5.4 and 0.4  0.3 /105PBMCs; p  0.02 and 0.001,respec-
tively). In allo-HSCT patients, anti-GPIIb/IIIa antibody-produc-
ing B cell frequency was signiﬁcantly greater in patients with
thrombocytopenia than in those without (7.3  7.3 vs 3.3  3.6;
p  0.009). Moreover, platelet count was negatively correlated
with anti-GPIIb/IIIa antibody-producing B cell frequency (r 0.3,
p  0.005). Of 18 platelet eluate samples, 13 had a detectable level
of anti-GPIIb/IIIa antibodies, whereas plasma anti-GPIIb/IIIa an-
tibodies were undetectable in all cases. Serial analysis of a patient
with thrombocytopenia who responded to corticosteroid therapy
Table. Hematopoietic Support in Short-term Culture
CD45
Cell
Expansion
Percent
CD34,
Day 12
CFU/100
Input
Cells
CFU
Expansion
Percent
CD7,
Day 12
AdS 3.78  1.1
fold
17.4  5.1
%
12.2  2.8
CFU
0.90  0.3
fold
28.6  5.6
%
MdS 3.4  1.3
fold
28.7  6.5
%
16.3  3.7
CFU
1.07  0.27
fold
19.5  4.2
%
P 0.127 0.002 0.062 0.366 0.003
n 8 8 8 8 6
Values reported are the average  SEM, P values are by t-test.
Poster Session II
68
